| North Richmond Center For Health | |
|
1501 3rd St North Richmond CA 94801-1516 | |
| (925) 957-5429 | |
| Not Available |
| Full Name | North Richmond Center For Health |
|---|---|
| Speciality | Clinic/center - Federally Qualified Health Center (fqhc) |
| Location | 1501 3rd St, North Richmond, California |
| Authorized Official Name and Position | Patrick M. Godley (COO / CFO) |
| Authorized Official Contact | 9259575401 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| North Richmond Center For Health 50 Douglas Dr Suite 391 Martinez CA 94553-4098 Ph: () - | North Richmond Center For Health 1501 3rd St North Richmond CA 94801-1516 Ph: (925) 957-5429 |
| NPI Number | 1447338694 |
|---|---|
| Provider Enumeration Date | 11/02/2006 |
| Last Update Date | 04/24/2024 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447338694 | NPI | - | NPPES |
| FHC80133F | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QF0400X | Clinic/center - Federally Qualified Health Center (fqhc) | 140000090 (California) | Primary |
News Archive
The healthcare negotiator for one of nation's most powerful unions made clear that it opposes a tax on high-cost-insurance plans, despite abstaining from an multi-union campaign objecting to the plan," The Hill reports. "The Service Employees International Union (SEIU) was not among the 27 unions to sign on to an ad criticizing a proposed tax on 'Cadillac' insurance plans that was included in the Senate Finance Committee healthcare bill."
Citing a federal government estimate that more than 3 million Californians cannot find doctors who will provide them essential medical care, health care and social justice advocates challenge the Senate to show the same level of compassion and leadership demonstrated by yesterday's passage of SB 726 (Ashburn) on the Assembly Floor.
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of Hodgkin lymphoma (HL). The Company is currently investigating pralatrexate in a number of ongoing studies, including a Phase 2 clinical study in patients with relapsed or refractory non-Hodgkin lymphoma or Hodgkin lymphoma.
New data to be presented at the Annual Congress of the European Respiratory Society (ERS 2012), in Vienna, Austria, will shed light on the current and potential future role of tiotropium, the first once-daily long-acting inhaled anticholinergic for patients with Chronic Obstructive Pulmonary Disease (COPD).
Global child deaths have reached a record low, falling below 10 million per year to 9.7 million, down from almost 13 million in 1990, according to UNICEF.
› Verified 8 days ago